Ultragenyx Pharmaceutical
RARE
81 hedge funds and large institutions have $816M invested in Ultragenyx Pharmaceutical in 2014 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 9 closing their positions.
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
19% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 26
17% more call options, than puts
Call options by funds: $293K | Put options by funds: $251K
5% more funds holding
Funds holding: 77 → 81 (+4)
0% more capital invested
Capital invested by funds: $815M → $816M (+$1.1M)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$37.4M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$7.32M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.34M |
| 4 |
CI
Cowen Inc
New York
|
+$5.78M |
| 5 |
Goldman Sachs
New York
|
+$2.67M |
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$5.67M |
| 2 |
TCP
Tourbillon Capital Partners
New York
|
-$3.91M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.45M |
| 4 |
Jennison Associates
New York
|
-$2.68M |
| 5 |
Millennium Management
New York
|
-$2.63M |
RARE Hedge Fund Activity: Q2 2014 in Review
81 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2014, worth a combined $816M — up 0.14% from $815M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new RARE positions and 9 closed out — a net gain of 5 holders — while 31 added to existing stakes and 26 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $37.4M. The largest seller was T. Rowe Price Associates, cutting an estimated $5.67M.
- 81 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2014, up from 77 in Q1 2014.
- Funds reported $816M of Ultragenyx Pharmaceutical stock for Q2 2014, up 0.14% quarter-over-quarter.
- 14 funds opened new Ultragenyx Pharmaceutical positions in Q2 2014 and 9 closed out, a net change of +5 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2014 was Fidelity Investments, an estimated $37.4M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2014 was T. Rowe Price Associates, an estimated $5.67M sold.
Based on aggregated 13F filings for Q2 2014.